A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period

Primary Objective: To compare LixiLan to lixisenatide in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 diabetes mellitus. Secondary Objective: To compare the overall efficacy and safety of LixiLan to lixisenatide (with or without OADs) over a 52 week treatment period in patients with type 2 diabetes mellitus.

主要研究目的：对比LixiLan与利司那肽（lixisenatide）在2型糖尿病患者中，糖化血红蛋白（glycated hemoglobin, HbA1c）从基线至第26周的变化幅度。次要研究目的：在2型糖尿病患者中，对比LixiLan与利司那肽（联合或不联合口服降糖药（Oral Antidiabetic Drugs，简称OADs））在52周治疗周期内的总体有效性与安全性。